SangStat wins patent for cyclosporine, setting stage for a battle with Novartis

Article Abstract:

SangStat Medical Corp. won a U.S. patent for a new form of cyclosporine. The drug is used to prevent rejection of transplanted organs. The small Menlo Park, California company is breaking into a market dominated by Swiss pharmaceuticals giant Novartis AG. SangStat's planned market invasion could be complicated by Novartis' huge sales force. SangStat has allied with Eli Lilly and Co. in manufaturing its drug. There are more than 200,000 patients on cyclosporine in the U.S. and Europe.

Comment:

Won a U.S. patent for cyclosporine

Company Planning/Goals, Antiinfective Preparations, Patents & copyrights, Anti-infective agents, Article

---

Roche Holding's Xenical helps patients keep the weight off for up to 2 years

Article Abstract:

Swiss pharmaceutical firm Roche Holding Ltd. is having success with sales of its new weight loss pill in Europe, but it is still considered experimental and the FDA in the US asked for more data. The FDA's concerns were with possible increased incidence of breast cancer from using the drug. Xenical works directly on the stomach to keep the body from absorbing fat. Side effects reported have been bloating and cramps.

Comment:

Co. submitted more data to FDA on Xenical

Foreign operations, Switzerland, Anorexigenics, Investigations, Testing, Appetite depressants, United States. Food and Drug Administration, Roche Holding Ltd., Weight reducing preparations, Anti-obesity agents

---

SangStat wins FDA approval to market drug for use after organ transplants

Article Abstract:

California-based SangStat Medical Corp. will market the generic drug, SangCya, a cyclosporine that prevents rejection of transplanted organs. The drug has been under FDA review for about two years. SangStat's sales force of only 33 need only target the 100 hospitals where transplants are performed in the U.S. The drug's brand-name counterpart is Neoral from Novartis AG based in Switzerland.

Marketing procedures, Generic Drugs, Transplantation of organs, tissues, etc., Organ transplantation, Tissue transplantation, Transplantation, SANG

Similar abstracts:

• Abstracts: British Air's new no-frills carrier, Go, to battle its discount rivals. AMR-British air linkup just keeps circling, circling
• Abstracts: Hidden costs in on-line trading; new networks unsettle markets
• Abstracts: Cargill searches for a corporate identity. Monsanto's cost-cutting steps to raise cash for seed-company acquisitions
• Abstracts: Tyco agrees to buy AMP for $11.3 billion. Anne Klein said to be for sale, with its name as biggest draw
• Abstracts: Lycos, amassing sites and surfers, aims higher. USA Networks to merge with Lycos

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.